HRP20020664B1 - Primjena 1,2-diarilbenzimidazola pri utvrđivanju oboljenja povezanih sa aktivacijom stanica mikroglije - Google Patents

Primjena 1,2-diarilbenzimidazola pri utvrđivanju oboljenja povezanih sa aktivacijom stanica mikroglije

Info

Publication number
HRP20020664B1
HRP20020664B1 HR20020664A HRP20020664A HRP20020664B1 HR P20020664 B1 HRP20020664 B1 HR P20020664B1 HR 20020664 A HR20020664 A HR 20020664A HR P20020664 A HRP20020664 A HR P20020664A HR P20020664 B1 HRP20020664 B1 HR P20020664B1
Authority
HR
Croatia
Prior art keywords
substituents
aryl
diyl
group
dihydro
Prior art date
Application number
HR20020664A
Other languages
English (en)
Croatian (hr)
Inventor
Kuhnke Joachim
Halfbrodt Wolfgang
Moenning Ursula
Original Assignee
Bayer Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma Aktiengesellschaft filed Critical Bayer Pharma Aktiengesellschaft
Publication of HRP20020664A2 publication Critical patent/HRP20020664A2/hr
Publication of HRP20020664B1 publication Critical patent/HRP20020664B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HR20020664A 2000-01-14 2001-01-12 Primjena 1,2-diarilbenzimidazola pri utvrđivanju oboljenja povezanih sa aktivacijom stanica mikroglije HRP20020664B1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10002898 2000-01-14
PCT/EP2001/000334 WO2001051473A1 (de) 2000-01-14 2001-01-12 1,2-diarylbenzimidazole zur behandlung von krankungen die mit einer microglia-aktivierung assoziiert sind

Publications (2)

Publication Number Publication Date
HRP20020664A2 HRP20020664A2 (en) 2005-04-30
HRP20020664B1 true HRP20020664B1 (hr) 2012-03-31

Family

ID=7628535

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20020664A HRP20020664B1 (hr) 2000-01-14 2001-01-12 Primjena 1,2-diarilbenzimidazola pri utvrđivanju oboljenja povezanih sa aktivacijom stanica mikroglije

Country Status (31)

Country Link
EP (1) EP1246808B1 (cs)
JP (1) JP2003523961A (cs)
KR (1) KR100703908B1 (cs)
CN (1) CN1301975C (cs)
AT (1) ATE520669T1 (cs)
AU (1) AU782993B2 (cs)
BG (1) BG65858B1 (cs)
BR (1) BR0107628A (cs)
CA (1) CA2396227C (cs)
CY (1) CY1112962T1 (cs)
CZ (1) CZ303726B6 (cs)
DK (1) DK1246808T3 (cs)
EA (1) EA006302B1 (cs)
EE (1) EE05515B1 (cs)
ES (1) ES2372026T3 (cs)
HR (1) HRP20020664B1 (cs)
HU (1) HU228366B1 (cs)
IL (2) IL150150A0 (cs)
ME (1) MEP13308A (cs)
MX (1) MXPA02005742A (cs)
NO (1) NO326408B1 (cs)
NZ (1) NZ519326A (cs)
PL (1) PL209573B1 (cs)
PT (1) PT1246808E (cs)
RS (1) RS51860B (cs)
SI (1) SI1246808T1 (cs)
SK (1) SK287527B6 (cs)
TW (1) TWI287005B (cs)
UA (1) UA75589C2 (cs)
WO (1) WO2001051473A1 (cs)
ZA (1) ZA200206470B (cs)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6855714B2 (en) 2001-07-06 2005-02-15 Schering Aktiengesellschaft 1-alkyl-2-aryl-benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives
DE10134775A1 (de) * 2001-07-06 2003-01-30 Schering Ag 1-Alkyl-2.aryl-benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate
US6903126B2 (en) 2001-07-09 2005-06-07 Schering Ag 1-Aryl-2-N-, S- or O-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives
DE10135050A1 (de) * 2001-07-09 2003-02-06 Schering Ag 1-Ary1-2-N-, S- oder O-substituierte Benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate
DE10207844A1 (de) * 2002-02-15 2003-09-04 Schering Ag 1-Phenyl-2-heteroaryl-substituierte Benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate
US6962932B2 (en) 2002-02-15 2005-11-08 Schering Aktiengesellschaft 1-phenyl-2-heteroaryl-substituted benzimdazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives
DE10207843A1 (de) * 2002-02-15 2003-09-04 Schering Ag Mikrolia-Inhibitoren zur Unterbrechung von Interleukin 12 und IFN-gamma vermittelten Immunreaktionen
CA2518318A1 (en) * 2003-03-17 2004-09-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
SE0302573D0 (sv) * 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302570D0 (sv) * 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
ATE545644T1 (de) 2004-09-24 2012-03-15 Astrazeneca Ab Benzimidazolderivate, diese enthaltende zusammensetzungen, herstellung davon und anwendungen davon i
TW200745049A (en) 2006-03-23 2007-12-16 Astrazeneca Ab New crystalline forms
TW200808769A (en) 2006-04-18 2008-02-16 Astrazeneca Ab Therapeutic compounds
JP5255994B2 (ja) * 2008-11-04 2013-08-07 国立大学法人 岡山大学 核内受容体リガンド
US9382226B2 (en) 2010-07-21 2016-07-05 Merck Sharp & Dohme Corp. Aldosterone synthase inhibitors
CN102382102B (zh) * 2010-09-06 2014-01-08 中国科学院广州生物医药与健康研究院 一种酰胺类化合物
BR112014020345B1 (pt) * 2012-02-17 2021-09-21 Kineta Four Llc Composto antiviral, composição farmacêutica compreendendo dito composto e uso dos mesmos para tratar infecção viral ou doença associada à mesma
WO2014044611A1 (en) 2012-09-20 2014-03-27 Bayer Pharma Aktiengesellschaft 1-aryl-2-heteroaryl benzimidazoles for the induction of neuronal regeneration
DK3390367T3 (da) * 2015-12-15 2020-10-26 Univ Leland Stanford Junior Fremgangsmåde til forebyggelse og/eller behandling af aldersrelateret kognitiv funktionsnedsættelse og neuroinflammation
MX2021003904A (es) 2018-10-05 2021-10-26 Annapurna Bio Inc Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor apj.

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0104727A1 (en) * 1982-08-13 1984-04-04 The Upjohn Company Pyridinyl-substituted benzimidazoles and quinoxalines
EP0520200A2 (en) * 1991-06-24 1992-12-30 Neurosearch A/S Imidazole compounds, their preparation and use
EP0528164A2 (de) * 1991-07-11 1993-02-24 Hoechst Aktiengesellschaft Verwendung von Xanthinderivaten zur Herstellung eines Arzneimittels zur Behandlung von sekundären Nervenzellschäden und Funktionsstörungen nach Schädel-Hirn-Traumen
EP0531883A1 (de) * 1991-09-06 1993-03-17 Dr. Karl Thomae GmbH Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
WO1995007263A1 (de) * 1993-09-09 1995-03-16 Schering Aktiengesellschaft 1,2-di(het)aryl-benzimidazol derivate, deren herstellung und deren verwendung als prostazyklin-(pgi2)-mimetika
US5552426A (en) * 1994-04-29 1996-09-03 Eli Lilly And Company Methods for treating a physiological disorder associated with β-amyloid peptide
WO1997012613A1 (en) * 1995-10-05 1997-04-10 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
WO1997033873A1 (en) * 1996-03-11 1997-09-18 Eli Lilly And Company Methods of treating or preventing interstitial cystitis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ270985A (en) * 1994-04-29 1997-06-24 Lilly Co Eli Substituted benzimidazole derivatives; medicaments and preparation of medicaments

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0104727A1 (en) * 1982-08-13 1984-04-04 The Upjohn Company Pyridinyl-substituted benzimidazoles and quinoxalines
EP0520200A2 (en) * 1991-06-24 1992-12-30 Neurosearch A/S Imidazole compounds, their preparation and use
EP0528164A2 (de) * 1991-07-11 1993-02-24 Hoechst Aktiengesellschaft Verwendung von Xanthinderivaten zur Herstellung eines Arzneimittels zur Behandlung von sekundären Nervenzellschäden und Funktionsstörungen nach Schädel-Hirn-Traumen
EP0531883A1 (de) * 1991-09-06 1993-03-17 Dr. Karl Thomae GmbH Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
WO1995007263A1 (de) * 1993-09-09 1995-03-16 Schering Aktiengesellschaft 1,2-di(het)aryl-benzimidazol derivate, deren herstellung und deren verwendung als prostazyklin-(pgi2)-mimetika
US5552426A (en) * 1994-04-29 1996-09-03 Eli Lilly And Company Methods for treating a physiological disorder associated with β-amyloid peptide
WO1997012613A1 (en) * 1995-10-05 1997-04-10 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
WO1997033873A1 (en) * 1996-03-11 1997-09-18 Eli Lilly And Company Methods of treating or preventing interstitial cystitis

Also Published As

Publication number Publication date
IL150150A0 (en) 2002-12-01
HUP0204011A2 (en) 2003-05-28
SI1246808T1 (sl) 2011-12-30
ATE520669T1 (de) 2011-09-15
BR0107628A (pt) 2002-10-08
MEP13308A (en) 2010-10-10
UA75589C2 (en) 2006-05-15
BG65858B1 (bg) 2010-03-31
RS51860B (sr) 2012-02-29
WO2001051473A8 (de) 2002-01-03
YU45702A (sh) 2005-03-15
AU782993B2 (en) 2005-09-15
SK10002002A3 (sk) 2003-02-04
NZ519326A (en) 2005-02-25
HRP20020664A2 (en) 2005-04-30
CN1301975C (zh) 2007-02-28
HU228366B1 (en) 2013-03-28
EA200200742A1 (ru) 2002-12-26
EE200200390A (et) 2003-10-15
CZ20022420A3 (cs) 2002-10-16
KR100703908B1 (ko) 2007-04-05
EA006302B1 (ru) 2005-10-27
IL150150A (en) 2014-03-31
CA2396227A1 (en) 2001-07-19
BG106821A (bg) 2003-01-31
EE05515B1 (et) 2012-02-15
ES2372026T3 (es) 2012-01-13
WO2001051473A1 (de) 2001-07-19
EP1246808A1 (de) 2002-10-09
EP1246808B1 (de) 2011-08-17
MXPA02005742A (es) 2002-09-18
HUP0204011A3 (en) 2003-07-28
SK287527B6 (sk) 2011-01-04
DK1246808T3 (da) 2011-12-05
CY1112962T1 (el) 2016-04-13
CN1395568A (zh) 2003-02-05
NO326408B1 (no) 2008-12-01
TWI287005B (en) 2007-09-21
ZA200206470B (en) 2004-04-28
CA2396227C (en) 2012-03-20
NO20023362D0 (no) 2002-07-12
JP2003523961A (ja) 2003-08-12
PT1246808E (pt) 2011-11-30
NO20023362L (no) 2002-09-13
AU4233201A (en) 2001-07-24
PL356091A1 (en) 2004-06-14
PL209573B1 (pl) 2011-09-30
CZ303726B6 (cs) 2013-04-10
KR20020063629A (ko) 2002-08-03

Similar Documents

Publication Publication Date Title
HRP20020664B1 (hr) Primjena 1,2-diarilbenzimidazola pri utvrđivanju oboljenja povezanih sa aktivacijom stanica mikroglije
ATE282614T1 (de) Phenylharnstoff und phenylthioharnstoffderivate
CY1122863T1 (el) Φαρμακευτικη συνθεση που περιεχει γλυκοπυρρολικο και εναν αγωνιστη βητα2 αδρενοϋποδοχεα
TR200100574T2 (tr) Nitrojenöz heteroksiklik karboksamid türevlerini içeren antiviral ajanlar
EA200601263A1 (ru) Фосфорсодержащие производные пурина (варианты), лекарственное средство на их основе для воздействия на вирус папилломы человека и на опухолевые клетки (варианты)
TR200102237T2 (tr) N²-fenil amidin türevleri.
ES8801787A1 (es) Procedimiento para la obtencion de amidas de acidos benzoheterociclilalcanoicos
AR039789A1 (es) Pirazolopiridinas sustituidas con carbamato
CY1113118T1 (el) Παραγωγα πυριμιδινης
HUP9801711A2 (hu) Helyettesített imidazolidin-2,4-dion-vegyületek felhasználása fájdalomcsillapító szerként alkalmazható gyógyszerkészítmények előállítására
DK0535231T3 (da) Pyrimidinnucleosid-derivater
DK1021420T3 (da) Fremgangsmåde til fremstilling af triazolinthionderivater
MA28685B1 (fr) Derives de la quinazolinone, antagonistes de la vanilloide
DE602006020883D1 (de) Haftklebemittelzusammensetzung auf acrylatbasis
CR9532A (es) Compuestos con estructura de 1-(imidazol-2-il) amino-1,2-difeniletano para combatir plagas animales
DE68924556D1 (de) N-(N-(Tetrahydropyrido[2,3-d]pyrimidinylmethyl)-aminomethylbenzoyl)glutaminsäure-Derivate.
MX9206082A (es) Derivados de amida de acido n-fenil-2-ciano-3-hidroxicrotonico y su empleo como medicamentos con propiedades inmunomoduladoras.
BR0009265A (pt) Derivados com base em esfingóide e usos destes
ATE194346T1 (de) Stabile wässrige folinatlösung
DE69010262D1 (de) Purinyl- und Pyrimidinyl-tetrahydrofurane.
ES8305316A1 (es) Un procedimiento para la preparacion de guanidinas.
HRP20010194B1 (en) Benzoylguanidine derivatives with advantageous properties, method for producing them and their use in the production of medicaments
NZ512828A (en) Benzenic sulphonamide derivatives and their uses
AR025901A1 (es) (tio)amidas del acido n-fenil-fenoxinicotinico sustituidas
GB1088102A (en) Halogen substituted pyrido-pyrimidines

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
PNAN Change of the applicant name, address/residence

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, DE

PNAN Change of the applicant name, address/residence

Owner name: BAYER PHARMA AKTIENGESELLSCHAFT, DE

B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20130103

Year of fee payment: 14

PPPP Transfer of rights

Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE

PBON Lapse due to non-payment of renewal fee

Effective date: 20150112